Wire · opportunities
FDA grants IDE approval to Ciliatech for glaucoma implant study
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 10 September 2026 · Fusion42 review
The FDA has granted investigational device exemption (IDE) approval to Ciliatech for a U.S.-based clinical study of its glaucoma implant, the Intercil Uveal Spacer, following its CE certification in Europe. The study aims to evaluate the safety and performance of the implant in patients with primary open-angle glaucoma.
This Wire brief sits within Fusion42's coverage of Medtech, and 2 sources have reported it between 8 Sep 2026 and 10 Sep 2026.
◆ ◆ The Wire takeaway
You gain access to the U.S. market with FDA clearance enabling clinical trials for glaucoma implants. Accelerate partnerships with US clinics now to prepare for upcoming approvals and market entry.
◆ Coverage
2 sources · first reported 8 Sep 2026 · latest 10 Sep 2026
◆ Related on Wire
◆ Topics